Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tadashi Tatsumi is active.

Publication


Featured researches published by Tadashi Tatsumi.


Bioorganic & Medicinal Chemistry | 2003

Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. synthesis and biological evaluation of dihydropyridin-2(1H)-imines and 1,5,6,7-tetrahydro-2H-azepin-2-imines.

Yasufumi Kawanaka; Kaoru Kobayashi; Shinya Kusuda; Tadashi Tatsumi; Masayuki Murota; Toshihiko Nishiyama; Katsuya Hisaichi; Atsuko Fujii; Keisuke Hirai; Minoru Nishizaki; Masao Naka; Masaharu Komeno; Hisao Nakai; Masaaki Toda

The process of discovery and biological evaluation of alpha,beta-unsaturated cyclic amidines, as selective inhibitors of inducible nitric oxide synthase (iNOS), is reported. Dihydropyridin-2(1H)-imines and 1,5,6,7-tetrahydro-2H-azepin-2-imines were synthesized and biologically evaluated both in vitro and in vivo using a nitric oxide synthase inhibition assay. Compounds 1, 5, 6, 8-12 and 16 exhibited potent inhibition of iNOS. Among these, compounds 6, 7, 10, 11 and 16 showed 5- to 19-fold isoform selectivity. Compounds 1, 6, 10, 11 and 16 also showed potent inhibitory activity in the NOx accumulation assay in mice. Compounds 1 and 6 showed excellent bioavailability (BA) in rats when administered orally. Full details are presented here, including the structure-activity relationship (SAR) studies, the chemistry of these compounds, and the pharmacokinetic data and the computer-aided docking study of 10 with hiNOS.


Bioorganic & Medicinal Chemistry | 2003

Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Identification of 2-azabicyclo[4.1.0]heptan-3-imines.

Yasufumi Kawanaka; Kaoru Kobayashi; Shinya Kusuda; Tadashi Tatsumi; Masayuki Murota; Toshihiko Nishiyama; Katsuya Hisaichi; Atsuko Fujii; Keisuke Hirai; Masao Naka; Masaharu Komeno; Yshihiko Odagaki; Hisao Nakai; Masaaki Toda

Further chemical modification of 2-iminopiperidines fused to cyclopropane rings was performed. Optically active isomers 2 and 13 were synthesized and their biological activity was evaluated. Compound 2 exhibited greater potency and more isoform selectivity than enantiomer 13 in the iNOS inhibition assay. One of the gem-chlorines on the fused cyclopropane moiety of 2 was eliminated to produce 3, which showed reduced potency for iNOS inhibition, as well as 4 with an increased potency. The isoform selectivity of 4 was also much higher than that of 3. This was also true for the corresponding methyl derivatives 6-9. The structure-activity relationship (SAR) study and computer aided docking study of the most optimized structure 4 with human iNOS will also be reported.


European Journal of Medicinal Chemistry | 2003

Design and synthesis of inhibitors of inducible nitric oxide synthase. Discovery of a new chemical lead with potential for oral bioavailability

Yasufumi Kawanaka; Kaoru Kobayashi; Shinya Kusuda; Tadashi Tatsumi; Masayuki Murota; Toshihiko Nishiyama; Katsuya Hisaichi; Atsuko Fujii; Keisuke Hirai; Masao Naka; Masaharu Komeno; Hisao Nakai; Masaaki Toda

A series of 2-iminopiperidines fused to small-membered rings (Tables 1 and 2) were synthesised and biologically evaluated using an in vitro human nitric oxide synthase (NOS) inhibition assay. Fused bicyclic compounds 5-9 exhibited nearly the same potency as compound 1 in the hiNOS inhibition assay. Among these, the 1-methyl analogues 8 and 9 showed better isoform selectivity than their corresponding unsubstituted analogues 7 and 6, respectively. Compounds 5 and 6 were also evaluated by an in vivo NO accumulation assay in a mouse model. The discovery process of new chemical leads for an orally bioavailable inhibitor of human inducible NOS (iNOS) is reported. The structure-activity relationship (SAR) study and chemistry of these compounds are also reported.


Bioorganic & Medicinal Chemistry Letters | 2002

Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropyridin-2-imines

Yasufumi Kawanaka; Kaoru Kobayashi; Shinya Kusuda; Tadashi Tatsumi; Masanori Murota; Toshihiko Nishiyama; Katsuya Hisaichi; Atsuko Fujii; Keisuke Hirai; Masao Naka; Masaharu Komeno; Hisao Nakai; Masaaki Toda

Dihydropyridin-2-imines were synthesized and biologically evaluated both in vitro and in vivo using a nitric oxide inhibition assay. Compounds 1, 4, 5 and 7-11 exhibited potent activity in the inducible nitric oxide (iNOS) inhibition assay. Of these 5, 6, 9 and 10 showed 5- to 11-fold increases in isoform selectivity. Compounds 1, 5, 9 and 10 showed potent inhibitory activity in the NOx accumulation assay in mice. Compounds 1 and 5 also showed good bioavailability (BA) when given orally.


International Journal of Peptide Research and Therapeutics | 2007

Studies on Substrate Specificity at PR/p3 Cleavage Site of HTLV-1 Protease

Jeong Kyu Bang; Kenta Teruya; Saburo Aimoto; Hiroyuki Konno; Kazuto Nosaka; Tadashi Tatsumi; Kenichi Akaji

Substrate specificities for recognition at the PR/p3 site of HTLV-1 protease were clarified using small libraries of substrate peptides. Specificities at P1 and P1′ positions were examined by parallel synthesis/digestion of synthetic peptides covering the PR/p3 site (KGPPVILPIQA). Specificities at P2 to P4 positions were examined by split and mix syntheses of olefin-peptide libraries containing the substrate sequence (PPVILPIQ). The solid-phase Horner-Emmons reaction was successfully applied to syntheses of multi-component substrates for library preparation. From the digestion of substrate peptides by a chemically synthesized mutant of HTLV-1 protease (C2A HTLV-1 PR), it was found for the first time that the preference for Pro at the P1′ position and for Ile at the P2 position is unique for this enzyme.


Bioorganic & Medicinal Chemistry | 2010

Evaluation of retro-inverso modifications of HTLV-1 protease inhibitors containing a hydroxyethylamine isoster.

Tadashi Tatsumi; Chiyuki Awahara; Hiromi Naka; Saburo Aimoto; Hiroyuki Konno; Kazuto Nosaka; Kenichi Akaji

Effects of retro-inverso (RI) modifications of HTLV-1 protease inhibitors containing a hydroxyethylamine isoster backbone were clarified. Construction of the isoster backbone was achieved by a stereoselective aldol reaction. Four diastereomers with different configurations at the isoster hydroxyl site and the scissile site substituent were synthesized. Inhibitory activities of the new inhibitors suggest that partially modified RI inhibitors would interact with HTLV-1 protease in the same manner as the parent hydroxyethylamine inhibitor.


Bioorganic & Medicinal Chemistry | 2014

Effect of prime-site sequence of retro-inverso-modified HTLV-1 protease inhibitor

Chiyuki Awahara; Tadashi Tatsumi; Saki Furuta; Gen Shinjoh; Hiroyuki Konno; Kazuto Nosaka; Kazuya Kobayashi; Yasunao Hattori; Kenichi Akaji

The effects of additional substituents covering the prime-site of retro-inverso (RI)-modified HTLV-1 protease inhibitors containing a hydroxyethylamine isoster were clarified. Stereo-selective construction of the most potent isoster backbone was achieved by the Evans-aldol reaction. Addition of N-acetylated d-amino acid corresponding to the P2 site gave an RI-modified inhibitor showing superior inhibitory activity to the previous inhibitor. Inhibitory activities of the newly synthesized inhibitors suggest that partially modified RI inhibitors would interact with HTLV-1 protease in the same manner as the parent hydroxyethylamine inhibitor.


Archive | 1998

Fused pyrazine compounds

Kaoru Kobayashi; Tadashi Tatsumi; Kiyoyuki Sato; Hiroyuki Ohno


Bioorganic & Medicinal Chemistry Letters | 2006

Evaluations of substrate specificity and inhibition at PR/p3 cleavage site of HTLV-1 protease

Hiromi Naka; Kenta Teruya; Jeong Kyu Bang; Saburo Aimoto; Tadashi Tatsumi; Hiroyuki Konno; Kazuto Nosaka; Kenichi Akaji


Bioorganic & Medicinal Chemistry | 2006

Discovery of heteroaryl sulfonamides as new EP1 receptor selective antagonists

Atsushi Naganawa; Toshiaki Matsui; Tetsuji Saito; Masaki Ima; Tadashi Tatsumi; Shingo Yamamoto; Masayuki Murota; Hiroshi Yamamoto; Takayuki Maruyama; Shuichi Ohuchida; Hisao Nakai; Kigen Kondo; Masaaki Toda

Collaboration


Dive into the Tadashi Tatsumi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiroyuki Konno

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Kazuto Nosaka

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Keisuke Hirai

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kenichi Akaji

Kyoto Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chiyuki Awahara

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge